aortoiliac occlusive disease


Also found in: Wikipedia.

a·or·to·il·i·ac oc·clu·sive dis·ease

obstruction of the abdominal aorta and its main branches by atherosclerosis.

a·or·to·il·i·ac oc·clu·sive dis·ease

(ā-ōr'tō-il'ē-ak ŏ-klū'siv di-zēz')
Obstruction of the abdominal aorta and its main branches by atherosclerosis.
aortoiliac occlusive disease atherosclerotic obstruction of the abdominal aorta and its main branches, causing severe lower-limb ischaemia
References in periodicals archive ?
In June 1999, EPIX initiated a Phase III efficacy trial for AngioMARK to detect aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease or abdominal aortic aneurysm.
The most significant achievement of 1999 was the initiation at the end of the second quarter of our AngioMARK Phase III clinical trial for aortoiliac occlusive disease.
We are advancing the Phase III trial of AngioMARK for the detection of aortoiliac occlusive disease.
Lantheus imaging products include the echocardiography contrast agent DEFINITY[R] Vial for (Perflutren Lipid Microsphere) Injectable Suspension, an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, ABLAVAR[R] (gadofosveset trisodium), a first-in-class magnetic resonance agent indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease, TechneLite[R] (Technetium Tc 99m Generator), Cardiolite[R] (Kit for the Preparation of Technetium Tc 99m Sestamibi for Injection), and Thallium 201 (Thallous Chloride Tl 201 Injection).
Lantheus imaging products include the echocardiography contrast agent DEFINITY([R]) Vial for (Perflutren Lipid Microsphere) Injectable Suspension, an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border; ABLAVAR([R]) (gadofosveset trisodium), a first-in-class magnetic resonance agent indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease; TechneLite([R]) (Technetium Tc99m Generator), Cardiolite([R]) (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium 201 (Thallous Chloride Tl 201 Injection).
AngioMARK, which currently is in Phase III efficacy trials for the detection of aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease or abdominal aortic aneurysm, is being co-developed by EPIX and Mallinckrodt.
In addition to the ongoing Phase III clinical trials for aortoiliac occlusive disease, AngioMARK is currently in Phase II feasibility trials for coronary artery disease and breast cancer.
The blood clot agent will be the second contrast agent in EPIX's pipeline, which includes AngioMARK(TM), currently in a Phase III efficacy trial for the detection of aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease or abdominal aortic aneurysm.
AngioMARK, EPIX' and Mallinckrodt's intravascular MRI contrast agent, is currently in a pivotal Phase III trial to determine its efficacy for detecting aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease or abdominal aortic aneurysm.
NYSE: MKG) today jointly announced the start of a Phase III efficacy trial for AngioMARK (MS-325), the companies' intravascular MRI contrast agent in development for the detection of aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease or abdominal aortic aneurysm.
Lantheus imaging products include the echocardiography contrast agent DEFINITY[R] Vial for (Perflutren Lipid Microsphere) Injectable Suspension, an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, ABLAVAR([R]) (gadofosveset trisodium), a first-in-class magnetic resonance agent indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease, TechneLite([R])(Technetium Tc99m Generator), Cardiolite([R]) (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium 201 (Thallous Chloride Tl 201 Injection).
EPIX's current Phase III multi-center clinical trial compares the diagnostic accuracy of MS-325-enhanced MRA with that of X-ray angiography in patients with aortoiliac occlusive disease, a major component of peripheral vascular disease.